Volume 73, Issue 5_suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


monkeys were used to determine the immunogenicity of Pvs25 protein expressed in the zygote/ookinete surface. Animals were immunized in three times with 100 μg of Pvs25 formulated in Montanide ISA-720. Antibodies to Pvs25 detected by an enzyme-linked immunosorbent assay appeared by day 30 after the first immunization, with a peak of antibodies levels on day 150. These antibodies were still detectable on day 300. Plasma samples on day 150 from experimental group were able to completely block the development of the parasite in mosquitoes artificially fed with human isolates of . Immunized monkeys were infected with blood forms of the Salvador I strain and no boosting effect of blood infection on titers of antibodies to Pvs25 was observed despite the presence of infective gametocytes. In conclusion, Pvs25 protein formulated in Montanide ISA-720 induces efficient and long-lasting transmission-blocking antibodies that cannot be boosted by parasite infection.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 : 97–106. [Google Scholar]
  2. Kroeger A, Meyer R, Mancheno M, Gonzalez M, 1996. Health education for community-based malaria control: an intervention study in Ecuador, Colombia and Nicaragua. Trop Med Int Health 1 : 836–846. [Google Scholar]
  3. Stowers A, Carter R, 2001. Current developments in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1 : 619–628. [Google Scholar]
  4. Kocken CHM, Jansen J, Kaan AM, Beckers PJA, Ponnudurai T, Kaslow DC, Konings RNH, Schoerunakers JGG, 1993. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol Biochem Parasitol 61 : 59–68. [Google Scholar]
  5. Williamson KC, Fujioka H, Aikawa M, Kaslow DC, 1996. Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate. Mol Biochem Parasitol 78 : 161–169. [Google Scholar]
  6. Tsuboi T, Tachibana M, Kaneko TO, Torii M, 2003. Transmission-blocking vaccine of P. vivax malaria. Parasitol Int 52 : 1–11. [Google Scholar]
  7. Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB, 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 62 : 5576–5580. [Google Scholar]
  8. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC, 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 174 : 1203–1208. [Google Scholar]
  9. Gozar MM, Price VL, Kaslow DC, 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun 66 : 59–64. [Google Scholar]
  10. Williamson KC, Keister DB, Muratova O, Kaslow DC, 1995. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol 75 : 33–42. [Google Scholar]
  11. Milek RL, Roeffen WF, Kocken CH, Jansen J, Kaan AM, Eling WM, Sauerwein RW, Konings RN, 1998. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Parasite Immunol 20 : 377–385. [Google Scholar]
  12. Hisaeda H, Collins WE, Saul A, Stowers AW, 2001. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. Vaccine 20 : 763–770. [Google Scholar]
  13. Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC, 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68 : 6618–6623. [Google Scholar]
  14. Arakawa T, Tsuboi T, Kishimoto A, Sattabongkot J, Suwanabun N, Rungruang T, Matsumoto Y, Tsuji N, Hisaeda H, Stowers A, Shimabukuro I, Sato Y, Torii M, 2003. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 21 : 3143–3148. [Google Scholar]
  15. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A, 2005. Phase I vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 : 3131–3138. [Google Scholar]
  16. Salas ML, Romero JF, Solarte Y, Olano V, Herrera MA, Herrera S, 1994. Development of sporogonic cycle of Plasmodium vivax in experimentally infected Anopheles albimanus mosquitoes. Mem Inst Oswaldo Cruz 89 : 115–119. [Google Scholar]
  17. Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arevalo-Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 91 : 49–60. [Google Scholar]
  18. Mu J, Duan J, Makova KD, Joy DA, Huynh CQ, Branch OH, Li WH, Su XZ, 2002. Chromosome-wide SNPs reveal an ancient origin for Plasmodium falciparum. Nature 418 : 323–326. [Google Scholar]
  19. Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, Parise ME, Steketee RW, 2003. Malaria surveillance–United States, 2001. MMWR Surveill Summ 52 : 1–14. [Google Scholar]
  20. Doberstyn EB, Teerakiartkamjorn C, Andre RG, Phintuyothin P, Noeypatimanondh S, 1979. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg 73 : 15–17. [Google Scholar]
  21. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, Irving DO, Briggs WR, Mai A, Ginny M, Adiguma T, Rare L, Giddy A, Reber-Liske R, Stuerchler D, Alpers MP, 2000. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18 : 2504–2511. [Google Scholar]
  22. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Sturchler D, 1999. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17 : 3145–3159. [Google Scholar]
  23. Fries HCW, Lamers MBAC, van Deursen J, Ponnudurai T, Meuwissen JHET, 1990. Biosynthesis of the 25-kDa protein in the macrogametes/zygotes of Plasmodium falciparum. Exp Parasitol 71 : 229–235. [Google Scholar]
  24. del Carmen Rodriguez M, Gerold P, Dessens J, Kurtenbach K, Schwartz RT, Sinden RE, Margos G, 2000. Characterisation and expression of pbs25, a sexual and sporogonic stage specific protein of Plasmodium berghei. Mol Biochem Parasitol 110 : 147–159. [Google Scholar]
  25. Vermeulen AN, van Deursen J, Brakenhoff RH, Lensen TH, Ponnudurai T, Meuwissen JH, 1986. Characterization of Plasmodium falciparum sexual stage antigens and their biosynthesis in synchronised gametocyte cultures. Mol Biochem Parasitol 20 : 155–163. [Google Scholar]
  26. Paton MG, Barker GC, Matsuoka H, Ramesar J, Janse CJ, Waters AP, Sinden RE, 1993. Structure and expression of a post-transcriptionally regulated malaria gene encoding a surface protein from the sexual stages of Plasmodium berghei. Mol Biochem Parasitol 59 : 263–275. [Google Scholar]

Data & Media loading...

  • Received : 13 Apr 2005
  • Accepted : 06 Jun 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error